Literature DB >> 23206954

Induction of sulfadiazine resistance in vitro in Toxoplasma gondii.

C Doliwa1, S Escotte-Binet, D Aubert, F Velard, A Schmid, R Geers, I Villena.   

Abstract

We induced sulfadiazine resistance in two sulfadiazine sensitive strains of Toxoplasma gondii, RH (Type I) and ME-49 (Type II) in vitro by using drug pressure. At first, sulfadiazine susceptibility of the two sensitive strains and two naturally resistant strains of T. gondii was evaluated on Vero cells using an enzyme-linked immunosorbent assay (ELISA). The IC(50) values of sulfadiazine were 77 μg/mL for RH, 51 μg/mL for ME-49 and higher than 1000 μg/mL for the two natural resistant strains. Secondly, induced resistance of the strains by gradually increase sulfadiazine concentration was verified by this test, which resulted IC(50) values at higher than 1000 μg/mL. In conclusion we developed in vitro two sulfadiazine resistant strains called RH-R(SDZ) and ME-49-R(SDZ). These strains resistant to sulfadiazine would be useful to characterize resistance mechanisms to sulfadiazine.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23206954     DOI: 10.1016/j.exppara.2012.11.019

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  14 in total

1.  Reduction of Toxoplasma gondii Development Due to Inhibition of Parasite Antioxidant Enzymes by a Dinuclear Iron(III) Compound.

Authors:  J A Portes; T G Souza; T A T dos Santos; L L R da Silva; T P Ribeiro; M D Pereira; A Horn; C Fernandes; R A DaMatta; W de Souza; S H Seabra
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

2.  Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis.

Authors:  Katarzyna Dzitko; Agata Paneth; Tomasz Plech; Jakub Pawełczyk; Lidia Węglińska; Piotr Paneth
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

3.  Sulfadiazine Sodium Ameliorates the Metabolomic Perturbation in Mice Infected with Toxoplasma gondii.

Authors:  Chun-Xue Zhou; Yun Gan; Hany M Elsheikha; Xiao-Qing Chen; Hua Cong; Qing Liu; Xing-Quan Zhu
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

4.  Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells.

Authors:  Katarzyna Dzitko; Marcin Mikołaj Grzybowski; Jakub Pawełczyk; Bożena Dziadek; Justyna Gatkowska; Paweł Stączek; Henryka Długońska
Journal:  Parasit Vectors       Date:  2015-08-15       Impact factor: 3.876

5.  Theileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor.

Authors:  Siddra A Hines; Joshua D Ramsay; Lowell S Kappmeyer; Audrey Ot Lau; Kayode K Ojo; Wesley C Van Voorhis; Donald P Knowles; Robert H Mealey
Journal:  Parasit Vectors       Date:  2015-01-20       Impact factor: 3.876

6.  Discovery of New Inhibitors of Toxoplasma gondii via the Pathogen Box.

Authors:  Jérémy Spalenka; Sandie Escotte-Binet; Ali Bakiri; Jane Hubert; Jean-Hugues Renault; Frédéric Velard; Simon Duchateau; Dominique Aubert; Antoine Huguenin; Isabelle Villena
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

7.  Genetic Polymorphisms and Phenotypic Profiles of Sulfadiazine-Resistant and Sensitive Toxoplasma gondii Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil.

Authors:  Letícia Azevedo Silva; João Luís Reis-Cunha; Daniella Castanheira Bartholomeu; Ricardo Wagner Almeida Vítor
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240

Review 8.  Drug Resistance in Toxoplasma gondii.

Authors:  Mahbobeh Montazeri; Saeed Mehrzadi; Mehdi Sharif; Shahabeddin Sarvi; Asal Tanzifi; Sargis A Aghayan; Ahmad Daryani
Journal:  Front Microbiol       Date:  2018-10-29       Impact factor: 5.640

9.  Sulfadiazine resistance in Toxoplasma gondii: no involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transporters.

Authors:  Christelle Doliwa; Sandie Escotte-Binet; Dominique Aubert; Virginie Sauvage; Frédéric Velard; Aline Schmid; Isabelle Villena
Journal:  Parasite       Date:  2013-05-27       Impact factor: 3.000

10.  Determination of lumefantrine as an effective drug against Toxoplasma gondii infection - in vitro and in vivo study.

Authors:  Dawei Wang; Mengen Xing; Saeed El-Ashram; Yingying Ding; Xiao Zhang; Xiaoyu Sang; Ying Feng; Ran Chen; Xinyi Wang; Ning Jiang; Qijun Chen; Na Yang
Journal:  Parasitology       Date:  2020-10-22       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.